Upgrade to SI Premium - Free Trial

AstraZeneca (AZN) Announces Brilinta/Brilique SOCRATES Trial Missed Primary Endpoint

March 23, 2016 7:14 AM
AstraZeneca (NYSE: AZN) announced the top-line results of the SOCRATES trial, assessing the efficacy of Brilinta/Brilique (ticagrelor) 90mg tablets twice ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Hot Corp. News Management Comments

Next Articles